MX2022005862A - Metodos de tratamiento de anemia hemolitica autoinmune caliente mediante el uso de anticuerpos anti-fcrn. - Google Patents

Metodos de tratamiento de anemia hemolitica autoinmune caliente mediante el uso de anticuerpos anti-fcrn.

Info

Publication number
MX2022005862A
MX2022005862A MX2022005862A MX2022005862A MX2022005862A MX 2022005862 A MX2022005862 A MX 2022005862A MX 2022005862 A MX2022005862 A MX 2022005862A MX 2022005862 A MX2022005862 A MX 2022005862A MX 2022005862 A MX2022005862 A MX 2022005862A
Authority
MX
Mexico
Prior art keywords
methods
hemolytic anemia
autoimmune hemolytic
warm autoimmune
treating warm
Prior art date
Application number
MX2022005862A
Other languages
English (en)
Spanish (es)
Inventor
Christine Morel Coquery
Jonathon Andrew Kluft
Iii William Thomas Symonds
Original Assignee
Immunovant Sciences Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Immunovant Sciences Gmbh filed Critical Immunovant Sciences Gmbh
Publication of MX2022005862A publication Critical patent/MX2022005862A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/283—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against Fc-receptors, e.g. CD16, CD32, CD64
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Transplantation (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
MX2022005862A 2019-11-19 2020-11-18 Metodos de tratamiento de anemia hemolitica autoinmune caliente mediante el uso de anticuerpos anti-fcrn. MX2022005862A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962937395P 2019-11-19 2019-11-19
PCT/US2020/061028 WO2021101975A1 (en) 2019-11-19 2020-11-18 Methods of treating warm autoimmune hemolytic anemia using anti-fcrn antibodies

Publications (1)

Publication Number Publication Date
MX2022005862A true MX2022005862A (es) 2022-06-23

Family

ID=73854886

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022005862A MX2022005862A (es) 2019-11-19 2020-11-18 Metodos de tratamiento de anemia hemolitica autoinmune caliente mediante el uso de anticuerpos anti-fcrn.

Country Status (10)

Country Link
US (1) US20230049011A1 (cg-RX-API-DMAC7.html)
EP (1) EP4061486A1 (cg-RX-API-DMAC7.html)
JP (1) JP7722991B2 (cg-RX-API-DMAC7.html)
CN (1) CN114728180A (cg-RX-API-DMAC7.html)
AU (1) AU2020387399A1 (cg-RX-API-DMAC7.html)
CA (1) CA3157797A1 (cg-RX-API-DMAC7.html)
IL (1) IL292889A (cg-RX-API-DMAC7.html)
MX (1) MX2022005862A (cg-RX-API-DMAC7.html)
TW (1) TW202132346A (cg-RX-API-DMAC7.html)
WO (1) WO2021101975A1 (cg-RX-API-DMAC7.html)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN117693523A (zh) * 2021-08-13 2024-03-12 舒泰神(北京)生物制药股份有限公司 特异性识别fcrn的抗体及其用途
AU2023281650A1 (en) 2022-05-30 2024-10-17 Hanall Biopharma Co., Ltd. Anti-fcrn antibody or antigen binding fragment thereof with improved stability
JP2025528527A (ja) * 2022-09-06 2025-08-28 イミュノバント・サイエンシズ・ゲーエムベーハー 抗FcRN抗体を用いたグレーブス病の治療方法
WO2026136830A1 (en) * 2024-12-20 2026-06-25 Paragon Therapeutics, Inc. Anti-fcrn antibodies and methods of use thereof

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4241852A3 (en) 2014-04-30 2023-11-15 Hanall Biopharma Co., Ltd. Antibody binding to fcrn for treating autoimmune diseases
US10336825B2 (en) * 2014-04-30 2019-07-02 Hanall Biopharma Co., Ltd. Antibody binding to FcRn for treating autoimmune diseases
JP6853178B2 (ja) * 2015-01-30 2021-03-31 モメンタ ファーマシューティカルズ インコーポレイテッド FcRn抗体およびその使用方法
CA3022547A1 (en) * 2015-05-12 2016-11-17 Syntimmune, Inc. Humanized affinity matured anti-fcrn antibodies
BR112019001806A2 (pt) * 2016-07-29 2019-05-07 Momenta Pharmaceuticals, Inc. anticorpos para fcrn e métodos de uso dos mesmos
EP3762027A4 (en) * 2018-02-13 2022-06-15 The Brigham & Women's Hospital, Inc. THERAPEUTIC FCRN-BASED BISPECIFIC MONOCLONAL ANTIBODIES

Also Published As

Publication number Publication date
CA3157797A1 (en) 2021-05-27
AU2020387399A1 (en) 2022-05-19
IL292889A (en) 2022-07-01
CN114728180A (zh) 2022-07-08
US20230049011A1 (en) 2023-02-16
TW202132346A (zh) 2021-09-01
WO2021101975A1 (en) 2021-05-27
EP4061486A1 (en) 2022-09-28
JP7722991B2 (ja) 2025-08-13
JP2023502398A (ja) 2023-01-24
KR20220100880A (ko) 2022-07-18

Similar Documents

Publication Publication Date Title
EA202191231A1 (ru) СПОСОБЫ ЛЕЧЕНИЯ ЭНДОКРИННОЙ ОФТАЛЬМОПАТИИ С ПРИМЕНЕНИЕМ АНТИ-FcRn АНТИТЕЛ
PH12020552018A1 (en) Entpd2 antibodies, combination therapies, and methods of using the antibodies and combination therapies
NZ777032A (en) Anti-nkg2a antibodies and uses thereof
MX392369B (es) Anticuerpos anti-ilt4 y fragmentos de union a antigeno.
MX2024013960A (es) Anticuerpos anti-ox40 y metodos de uso
MX2024006462A (es) Anticuerpos anti-tmprss2 y fragmentos de union a antigeno.
EA202092825A1 (ru) Анти-sirpa антитела и способы их применения
EP4241852A3 (en) Antibody binding to fcrn for treating autoimmune diseases
EA201992526A1 (ru) Стабильные составы анти-ctla4 антител, отдельно и в комбинации с антителами против рецептора 1 программируемой смерти (pd-1), и способы их применения
PH12021551500A1 (en) Anti-ctla4 antibodies and methods of use thereof
PH12020552006A1 (en) Antibodies specific for cd3 and uses thereof
PH12019501929A1 (en) Humanized antibody for treating or preventing cognitive disorders, process for producing the same, and agent for treating or preventing cognitive disorders using the same
MY205789A (en) Anti-gdf15 antibodies, compositions and methods of use
EP4374922A3 (en) Anti-c5 antibodies and uses thereof
GEP20207162B (en) Lag-3-binding molecules and methods of use thereof
WO2019060750A3 (en) A33 antibody compositions and methods of using the same in radioimmunotherapy
EA202091747A1 (ru) Составы антитела b7-h4
MX2024014570A (es) Activadores de linfocitos citoliticos naturales (nk) que se unen a las variantes de nkp46 y bcma con genomanipulacion de fc
MY208743A (en) Anti-ms4a4a antibodies and methods of use thereof
EP4276108A3 (en) Methods of treatment of diseases in which il-13 activity is detrimental using anti-il-13 antibodies
MX2021002750A (es) Anticuerpos anti-tnfrsf9 y usos de los mismos.
EA202090791A1 (ru) Агонистические антитела против cd40
WO2021048564A3 (en) Antigen-binding domain
EA201791691A1 (ru) ОДНОДОМЕННЫЕ АНТИТЕЛА, НАПРАВЛЕННЫЕ НА CD1d
MX2023004275A (es) Anticuerpos biespecificos anti-pd-1/cd40 y usos de los mismos.